Oramed Pre-IND for Diabetes Drug

Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) has submitted a pre-Investigational New Drug (pre-IND) meeting request to the FD) for a US-based trial on its orally ingestible exenatide capsule, ORMD-0901. The company’s orally ingestible insulin capsule (ORMD-0801) is currently in Phase 2 clinical trials on patients with type 2 diabetes (T2DM).Oramed recently announced that it has been granted a patent from Russia‚Äôs Federal Service for Intellectual Property, Patents and Trademarks (ROSPATENT) for its core concept of technology for the oral delivery of drugs currently delivered via injection. This patent has also been granted in New Zealand, South Africa and China.

Written by

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Etiam libero diam, elementum eget porttitor at, tincidunt at nulla.